To the Editor: Multiple primary lung cancer (MPLC) refers to the synchronous or metachronous appearance of more than one primary lung cancer in a single patient. The diagnosis of MPLC is complicated and it is often difficult to differentiate MPLC from metastatic lung cancers based on radiologic and histopathologic criteria alone. Moreover, the therapeutic regimens and prognosis for early MPLC and metastatic lung cancers are quite different.
metastases was considered. Subsequently, mutation analysis was performed and showed that the tumor cells in the RML lesion, but not the LUL lesion, harbored a mutation (19-del) within exon 19 of the EGFR gene. According to the Martini-Melamed diagnostic criteria [1] and the different EGFR molecular profiles of the bilateral lesions, the final diagnosis was MPLC. Given that the tumor, node, and metastasis stages of the LUL and the RML lesions were T2N0M0 and T1N0M0, respectively, and the patient's physical conditions, staging surgical resection was performed for the bilateral lesions. All of the resected lymph nodes were negative. The patient made an uneventful recovery and has had progression-free survival.
According to the literature, the incidence of MPLC is between 0.2% and 20.0%. [2] The American College of Chest Physicians [3] recommended new diagnostic criteria for MPLC in 2013; however, the diagnosis of MPLC is still complex, and it is often difficult to differentiate MPLC from lung cancer metastases, especially when the same histologic cell type is identified. Due to the significant differences in treatment plan and prognosis between MPLC and lung cancer metastases, the differential diagnosis is critical.
In this case, the fluorodeoxyglucose uptake of bilateral lesions did not enhance, thus benign lesions and early lung cancer were the initial working diagnosis. In this situation, we implemented a new diagnostic strategy, applying the Mayo risk prediction model analysis on the right GGO that eventually led to the final diagnosis.
The mathematical risk prediction model is an auxiliary diagnostic method to evaluate the likelihood of benign lesions or malignancies based on single nucleotide polymorphisms (SNPs). This model includes the patient's age, family history of cancer, tumor size, tumor angiogenesis, and other high-risk factors, which generates the likelihood of benign lesions or malignancies of SNPs. Due to the high sensitivity and specificity, the model is recognized by the industry. [4, 5] Thus, for early lung cancer, especially a negative PET-CT, the model can be an effective auxiliary diagnosis method.
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